Skip to content

Sensei Biotherapeutics

Clinical-Stage Biotechnology

About
Pipeline
Platform
Our Leadership
Careers
Investors and Media

About
Pipeline
Platform
Our Leadership
Careers
Investors and Media

Contact

Headquarters
451 D Street
Suite 710
Boston, MA 02210

Boston

Maryland location
1405 Research Blvd
Unit 125
Maryland, MD 20850

RB#7 (2)

About

We are biopharmaceutical company engaged in discovery, development, and delivery of next generation immunotherapies with an initial focus on treatments for cancer. We have developed two unique approaches – a TMAb™ (Tumor Microenvironment Activated biologics) platform, comprising unique human monoclonal antibodies and alpaca derived nanobodies that are selectively active in the tumor microenvironment, and an ImmunoPhage™ platform that leverages bacteriophage to fully engage the immune system. Using our TMAb platform, we developed SNS-101, an antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA). Using the ImmunoPhage platform, we are developing a library of ImmunoPhage, called Phortress™, with multiple tumor-associated antigens to create a personalized, yet off-the-shelf cocktail approach for treating cancer patients. This platform is designed to enable efficient, scalable and cost-effective manufacturing to support our clinical programs. SNS-401-NG is a next generation ImmunoPhage cocktail in preclinical development for the treatment of Merkel Cell Carcinoma.

Contact

Headquarters
451 D Street, Unit 710
Boston, MA 02210

Phone No

+1.240.243.8000

Maryland Location
1405 Research Blvd, Suite 125
Rockville, MD 20850

Email

info@senseibio.com

© 2022 Sensei Biotherapeutics. All Rights Reserved.

Privacy Policy

Footer